Strategies to manage hepatitis C virus (HCV) disease burden

Wedemeyer H., Duberg A. S., Buti M., Rosenberg W. M., Frankova S., Esmat G., ...Daha Fazla

JOURNAL OF VIRAL HEPATITIS, cilt.21, ss.60-89, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1111/jvh.12249
  • Dergi Adı: JOURNAL OF VIRAL HEPATITIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.60-89
  • Anahtar Kelimeler: diagnosis, epidemiology, HCV, mortality, treatment, scenarios, prevalence, incidence, hepatitis C, disease burden, SUSTAINED VIROLOGICAL RESPONSE, SINGLE-SOURCE OUTBREAK, PEGINTERFERON ALPHA-2B, HEPATOCELLULAR-CARCINOMA, TRIPLE THERAPY, TELAPREVIR, INFECTION, POPULATION, PREVALENCE, RIBAVIRIN
  • Ankara Üniversitesi Adresli: Evet

Özet

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.